Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CTNM
HOLDContineum Therapeutics, Inc. · Healthcare · United States · $526M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Contineum Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing novel small molecule therapies for neurological, inflammatory, and fibrotic diseases. The company's competitive potential hinges on the successful progression of its pipeline, including its lead candidate NIM8 for multiple sclerosis, through rigorous clinical trials to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 50.0M | 0 | 0 | — | — | — | 11.0M | -31.5% |
| EPS | -1.45 | 0.84 | -2.18 | -2.17 | — | -1.85 | -1.65 | -1.81 | — |
| Shares | 27.1M | 27.1M | 25.9M | 37.3M | +37.9% | 32.7M | — | — | — |
| Debt | 5.8M | 0.6M | 6.3M | 8.3M | 12.1% | 7.0M | — | — | — |
| Equity | -93.2M | -67.9M | 198.1M | 261.0M | 31.8% | — | — | — | — |
| Op CF | -20.1M | 19.3M | -32.8M | -55.3M | — | -57.2M | — | — | — |
| Inv CF | 22.3M | -65.6M | -69.7M | -3.7M | — | — | — | — | — |
| Fin CF | -1.2M | 56.2M | 109.0M | 112.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CTNM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc.(you) | $526M | 36 | HOLD |
| TECX | Tectonic Therapeutic, Inc. | $573M | 35 | HOLD |
| GYRE | Gyre Therapeutics, Inc. | $662M | 37 | HOLD |
| OVID | Ovid Therapeutics Inc. | $435M | 34 | SELL |
| CADL | Candel Therapeutics, Inc. | $700M | 35 | SELL |
| 0KCS.L | OPKO Health, Inc. | $734M | 37 | HOLD |
| IMMX | Immix Biopharma, Inc. | $607M | 31 | SELL |
| FDMT | 4D Molecular Therapeutics, Inc. | $526M | 28 | SELL |
| NGNE | Neurogene Inc. | $696M | 33 | SELL |
| OMER | Omeros Corporation | $709M | 33 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%